Cellectis S.A. Files September 2024 6-K Report

Ticker: CLLS · Form: 6-K · Filed: Sep 3, 2024 · CIK: 1627281

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer, sec-form-6k

TL;DR

Cellectis S.A. filed its monthly 6-K report on Sept 3, 2024, as required for foreign private issuers.

AI Summary

Cellectis S.A. filed a Form 6-K on September 3, 2024, to report information for the month of September 2024. The company, a biopharmaceutical firm based in Paris, France, is required to file this report under the Securities Exchange Act of 1934. Cellectis is a foreign private issuer and indicates it files annual reports under Form 20-F.

Why It Matters

This filing serves as an update for investors and the market regarding Cellectis S.A.'s regulatory reporting obligations as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine procedural report and does not contain new financial or operational information that would typically indicate a change in risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information that the company has made or is required to make public in its home country.

What is Cellectis S.A.'s standard industrial classification?

Cellectis S.A.'s Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].

Does Cellectis S.A. file annual reports under Form 20-F or 40-F?

Cellectis S.A. indicates it files annual reports under cover of Form 20-F.

What is the principal executive office address for Cellectis S.A.?

The principal executive office address for Cellectis S.A. is 8, rue de la Croix Jarry, 75013 Paris, France.

What is the filing date of this Form 6-K?

This Form 6-K was filed on September 3, 2024.

Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-09-03 16:35:29

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: September 3, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing